文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

四肢与躯干壁深部高恶性软组织肉瘤手术切除后负压伤口治疗效果——一项随机对照试验的研究方案

Effect of negative pressure wound therapy after surgical removal of deep-seated high-malignant soft tissue sarcomas of the extremities and trunk wall-study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2022-06-18

本研究为一项非盲、单中心随机对照试验,比较负压伤口治疗(NPWT)与常规伤口敷料在四肢或躯干壁深部高恶性软组织肉瘤手术切除后伤口并发症方面的效果。样本量计算为154例,主要终点为O'Sullivan等定义的重大伤口并发症,即术后4个月内因伤口修复需二次麻醉手术及无需二次手术的伤口处理。

要点

  • 非盲单中心随机对照试验,比较NPWT与常规敷料在深部高恶性软组织肉瘤术后的伤口并发症。
  • 样本量计算为154例,主要终点为术后4个月内O'Sullivan等定义的重大伤口并发症。
  • 试验已在ClinicalTrials.gov注册(NCT04960332),于2021年7月11日获批。

核心结论

  • 目前许多新医疗器械和技术不断引入,尽管NPWT在关节置换术等领域已有部分文献,但仍在软组织肉瘤手术中寻求该治疗原则的文献证据。

研究设计与样本

  • 非盲、单中心随机对照试验,比较NPWT与常规伤口敷料在四肢或躯干壁深部高恶性软组织肉瘤手术切除后的伤口并发症。
  • 样本量计算为154例软组织肉瘤患者(避免II类错误的风险80%,I类错误的风险5%,伤口并发症风险80%)。
  • 采用区组大小为8的区组随机化,分为A组(常规伤口敷料)和B组(NPWT,PREVENA PLUS™ Incision Management System)。
  • 纳入标准:因四肢或躯干壁深部软组织肉瘤接受手术。
  • 排除标准:年龄<18岁、整形手术、低恶性/交界性软组织肉瘤、化疗、术前放疗、对丙烯酸粘合剂或银过敏/高敏、不愿/无法提供知情同意、转移性疾病及缺血性手术。

主要发现

  • 主要研究终点为O'Sullivan等定义的重大伤口并发症,即术后4个月内因伤口修复需二次麻醉手术及无需二次手术的伤口处理。
  • 次要研究终点包括肌肉骨骼肿瘤学会评分(MSTS)、多伦多保肢评分(TESS)和欧洲五维健康量表(EQ-5D)。

关键数值与推荐

  • 主要终点重大伤口并发症采用O'Sullivan等定义:术后4个月内因伤口修复需二次麻醉手术及无需二次手术的伤口处理。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarcomas are a heterogeneous group of rare malignant tumors of mesenchymal origin in the musculoskeletal system. The main treatment is surgery often supplemented with pre-or postoperative radiotherapy. A retrospective study by Bedi et al. indicated that negative pressure wound therapy (NPWT) reduced the risk of postoperative wound complications in patients treated with preoperative radiation followed by surgical tumor removal of lower extremity soft tissue sarcomas (STS), and the use of NPWT was not associated with an increased risk of local recurrence. Previous studies have shown that NPWT can reduce postoperative complications. STS surgeries are a high-risk procedure concerning wound complications. METHODS: Non-blinded single-center randomized controlled trial comparing NPWT versus conventional wound dressing and postoperative wound complications after surgical removal of deep-seated high-malignant STS of the extremities or trunk wall Sample-size calculation: 154 STS patients (80% risk of avoiding type II error, 5% risk of type I error, and an 80% wound complication risk) Block randomization of 8 into: Group A: Conventional wound dressing Group B: NPWT (PREVENA PLUS™ Incision Management System) Inclusion criteria: Surgery for a deep-seated STS of an extremity or the trunk wall Exclusion criteria: Age < 18 years, plastic surgery, low malignant/borderline STS, chemotherapy, preoperative radiotherapy, allergic/hypersensitive to acrylic adhesives or silver, unwilling/unable to provide informed consent, metastatic disease, and ischemic surgeries Primary study endpoints were set as major wound complications defined by O'Sullivan et al. as a secondary surgery under anesthesia for wound repairs and wound management without secondary surgery within 4 months postoperatively. Secondary study endpoints among others are Musculoskeletal Tumor Society Score (MSTS), Toronto Extremity Salvage Score (TESS), and European Quality of Life - 5 Dimensions (EQ-5D). Approval from the Scientific Ethical Committee and the Data Protection Agency has been obtained, and the study is registered at clinicaltrial.gov . This study did not apply for external funding. DISCUSSION: Many new medical devices and technical solutions are currently being introduced, and even though some documentation regarding the use of NPWT, e.g., in joint replacement surgery exist, it is also important to seek documentation for this treatment principle in STS surgery. TRIAL REGISTRATION: Registered at ClinicalTrials.gov NCT04960332 and approved on 11 July 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yilmaz M, Thorn A, Sørensen MS, et al. Effect of negative pressure wound therapy after surgical removal of deep-seated high-malignant soft tissue sarcomas of the extremities and trunk wall-study protocol for a randomized controlled trial. Trials. 2022. PMID: 35717239. doi:10.1186/s13063-022-06468-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。